Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies

Qing Guo Xinyu Chen Lin-Feng Wu C. Ren You-Rong Jian Mingxi Lin Yi-Zi Jin C. Zeng Teng Zhou Yu-Xin Yan Yuan-Yuan Ruan Jian Zhang
Aug 2026 · Oncogene · Vol 45, pp. 4132 - 4148 · 0 citations · 54 references
Medicine

TL;DR

It is reported that primary HER2-specific targeted therapy (tucatinib) resistant or sensitive breast cancers derived from clinical trial patients exhibited differential protein profiles and was proposed as a promising therapeutic strategy for HER2-positive breast cancer.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Jul 2026

AARS1-catalyzed H4K12 lactylation promotes HCC resistance to targeted therapy by activating RAPGEF3-RAP1 signaling.

A novel metabolic-epigenetic mechanism whereby lactate modulates hepatocellular carcinoma sensitivity to targeted therapies through histone lactylation is delineated and suggests AARS1-H4K12la-RAPGEF3 axis may serve as an interventional target to overcome targeted drug resistance, offering a promising strategy to enhan...

Tanlun Zeng, Wanwan Zhu, Guanqun Sun et al. · 1 citation
Jul 2026

Abstract A088: SLC39A6-targeted combination therapy to reverse CAF-induced resistance in HER2+ breast cancer using a microfluidic platform

Findings identify SLC39A6 as a novel, actionable therapeutic target in CAF-rich HER2+ breast cancer and provide preclinical rationale for SLC39A6-directed ADC combination strategies, and establish a new paradigm for patient-specific drug screening in the context of the stromal tumor microenvironment.

Zeina S. Habli, Tiangyang Li, Mathew Poskus et al. · 0 citations
Open access Jul 2026

Targeting the adaptor protein Gab1 overcomes MET/Src-driven alectinib resistance in ALK-rearranged NSCLC.

In ALK-positive NSCLC with acquired resistance to alectinib, Gab1 emerged as a crucial downstream signaling convergence target of MET and Src co-activation, and targeting this adaptor protein presented a promising therapeutic strategy to overcome bypass-mediated resistance.

Heng-Yi Chen, Cai-yu Lin, Chen Hu et al. · 0 citations
Jul 2026

Tankyrase inhibition restores chemosensitivity in triple-negative breast cancer cells by disrupting TFEB/β-Catenin/ABCG2 axis

The study demonstrates that TFEB regulates the expression of the multidrug efflux transporter ATP-binding cassette subfamily G member 2 (ABCG2), a crucial factor in drug resistance mechanisms, and targets TNKS represents a potentially effective therapeutic approach to address cisplatin resistance and improve treatment...

Shariqa Jan, Kaneez Fatima, S. Khan et al. · 0 citations
Aug 2026

UNCX/SIN3A-Mediated H4K8 decrotonylation suppresses FOXO3 to drive TNBC progression and docetaxel resistance.

Uncoordinated homeobox (UNCX) is upregulated in docetaxel-resistant breast cancer cells, genomically amplified in breast cancer, and associated with poor survival in breast carcinoma patients, and established as a pivotal epigenetic regulator of TNBC progression and chemoresistance.

Song-Fu Shi, Dong Yan, Lixin Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.